Document:

Exhibit 10.115

 

LICENSE AGREEMENT

 

Between

 

VG Life Sciences,
Inc.

 

and

 

Scott & White
Healthcare

 

PATENT LICENSE
AGREEMENT NO. SW11-003PLA

 

 

This agreement ("Agreement") is made between VG Life
Sciences, Inc., a Delaware corporation with principal offices in San Marino, California, ("LICENSEE") and Scott &
White Healthcare, a Texas non profit corporation, with offices located at 2401 South 31st Street, Temple, TX 76508, on behalf of
itself and its Affiliates within its organizational structure ("S&W"), collectively referred to as "Parties"
and individually as "Party.''

 

W I T N E S S E T H:

 

WHEREAS, Dr. M. Karen Newell ("Dr. Newell"), an employee
of Texas A&M University Health Science Center ("HSC"), has invented either jointly or singly certain intellectual
property while employed byHSC;

 

WHEREAS, Dr. Newell, during the term of her employment at HSC,
has received salary support and other resources from S&W;

 

WHEREAS, HSC is a member of The Texas A&M University System
("SYSTEM'') and SYSTEM has responsibility for administering its intellectual property;

 

WHEREAS, S&W and SYSTEM have executed an Interinstitutional
Agreement, dated March 3, 2008, to define the relationship of S&W and SYSTEM as it relates to joint intellectual property and
transfers of rights therein, and that a Schedule 2 and a Schedule 8 ("Schedules") to the Interinstitutional Agreement,
dated March 20,2010, grant S&W the exclusive right to market and license the rights ofS&W and System to certain intellectual
property invented or co-invented by Dr. Newell on behalf of S&W and SYSTEM ;

 

WHEREAS, SYSTEM and S&W desire that such intellectual property
be commercialized for the public benefit and welfare; and

 

WHEREAS, LICENSEE has represented that it has certain marketing,
technical, and financial capabilities, and that it will undertake a thorough and diligent program of development and commercialization
of the LICENSED TECHNOLOGY; and

 

WHEREAS, S&W is willing to grant to LICENSEE, and LICENSEE
is willing to accept, a license to use S&W's and SYSTEM's rights in certain intellectual property invented or co-invented by
Dr. Newell, upon the terms and conditions below.

 

NOW THEREFORE, in consideration of the mutual covenants and
premises contained in this Agreement, the receipt and sufficiency of which is acknowledged, the Parties agree as follows:

 

    	1

    	 

    

 

ARTICLE I - DEFINITIONS

 

		1.1	"AFFILIATE" or "AFFILIATES" means any
entity that directly or indirectly owns or controls, is owned or controlled by, or under common ownership or control with a Party,
wherein "owns" as used in this definition means possession or the right to possession of at least 50% of the voting
stock of a corporation; and "controls" as used in this definition means (i) the power to direct the management and policies
of the entity or (ii) the power to appoint or remove a majority of the board of directors; or (iii) the right to receive 50% or
more of the profits or earnings.

 

		1.2	"PATENT RIGHTS"··means S&W's
and SYSTEM's rights in Table 1 in this Paragraph 1.2, all U.S., PCT and foreign patent applications claiming priority thereto,
all patents issuing therefrom, reissues, reexaminations and any extensions of or supplementary protection certificates allowed
on any of the foregoing, in each case only to the extent of subject matter claimed that is fully disclosed and enabled by the
disclosures in the patent applications below to satisfy 35 U.S.C. §112:

 

 

 

		1.3	"PROPRIETARY INFORMATION" means any know-how
and materials disclosed to Parties by Dr. Newell between March 20, 2010 and the Effective Date regarding the Patent Rights.

 

		1.4	"LICENSED PRODUCT" or "LICENSED PRODUCTS"
means any product, process, or composition of matter that is within the scope of any VALID CLAIM of PATENT RIGHTS.

 

 

    	2

    	 

    

 

 

 

		1.5	"VALID CLAIM" means and includes a claim of a
patent application or an unexpired patent or a patent whose expiration date has been extended by law, so long as the claim has
not been held invalid and/or unenforceable in an unappealable decision of a court or other authority of competent jurisdiction.

 

		1.6	"EFFECTIVE DATE.. means the date this Agreement has
been executed by the last Party.

 

		1.7	'"NET SALES" means LICENSEE's and SUBLICENSEE's
receipts for sales of LICENSED PRODUCTS or for services requiring the use of LICENSED PRODUCTS less the sum of the following:

 

		(a)	sales taxes, tariffs, duties and/or use taxes directly
imposed with reference to particular sales;

 

		(b)	outbound transportation prepaid or allowed; and

 

		(c)	amounts allowed or credited on returns.

 

Commissions paid to individuals, whether independent sales agents
or regularly employed by LICENSEE, and the cost of collections may not be deducted from NET SALES.

 

		1.8	"FIELD OF USE" means all uses.

 

		1.9	"TERRITORY" means world-wide.

 

		1.10	"LICENSEE" means VG Life Sciences, Inc. and any
entity in which VG Life Sciences, Inc. has an equity ownership share at least seventy five percent (75%).

 

		1.11	"SUBLICENSEE" means any third party sublicensed
by LICENSEE to make, have made, use, have used, sell, have sold, import, have imported, exported, or have exported LICENSED TECHNOLOGY.

 

		1.12	"LICENSED TECHNOLOGY" means technology that falls
within the scope of any VALID CLAIM of PATENT RIGHTS or any PROPRIETARY INFORMATION.

 

ARTICLE II - LICENSE GRANT

 

		2.1	Grant. S&W grants LICENSEE an exclusive license
under PATENT RIGHTS to make, have made, use. and sell the LICENSED PRODUCTS in the FIELD OF USE in the TERRITORY, and to grant
sublicenses of the same scope, to the end of the term of this Agreement as prescribed in Article VIII.

 

		2.2	Reservation. S&W on behalf of itself and SYSTEM
hereby reserves an irrevocable, nonexclusive, royalty-free right to practice the grant made in paragraph 2.1 for research, humanitarian,
and educational purposes only, and to grant sublicenses of the same scope, and not for commercial purposes or for the commercial
benefit of third parties.

 

		2.3	Government Reservation. To the extent that rights
under this Agreement are subject to rights required to be granted to the Government of the United States of America under 35 USC
Sections 200-212, such rights are so granted including a nonexclusive, nontransferable, irrevocable, paid-up license to practice
or have practiced for the United States the subject inventions throughout the world.

 

 

 

    	3

    	 

    

 

ARTICLE III - CONSIDERATION

 

		3.1	License Fee. In consideration for the license granted
in this Agreement, LICENSEE must make an initial payment in the amount fifty thousand dollars ($50,000) to S&W. This payment
is due no later than sixty (60) days after the EFFECTIVE DATE. Failure to make this payment within the specified period will cause
this Agreement to immediately terminate.

 

		3.2	Royalty Rate. As additional consideration for the
license granted in this Agreement, LICENSEE must remit to S&W a royalty of three percent (3%) of NET SALES in developed countries
and one half percent (0.5%) of NET SALES in underdeveloped countries. Underdeveloped countries shall mean any country which, at
the time the sale occurs, meets the definition of a developing country as defined by the World Bank. Developed countries shall
mean all countries other than underdeveloped countries as defined by the World Bank. LICENSEE may not accept anything of value
in lieu of money payment without the express written permission of S&W. When calculating NET SALES, S&W may assign fair
market value based upon comparable sales to receipts from transactions that are not made at fair market value.

 

		3.3	No Multiple Royalties. No multiple royalties shall
be payable because any LICENSED PRODUCT is covered by more than one of the PATENT RIGHTS.

 

		3.4	Reduction in Royalty Rate. In the event that LICENSEE
must enter into a license with a third party and agrees to pay a royalty thereunder in order to make, use, or sell a LICENSED
PRODUCT or sublicense PATENT RIGHTS, then any such royalty shall be reduced by fifty percent (50%) of the royalty paid to said
third party for the same reporting period. However, in no event shall any such royalty be less than one half the otherwise applicable
royalties.

 

		3.5	Minimum Annual Consideration. In order to maintain
this license to PATENT RIGHTS, LICENSEE must pay S&W minimum annual consideration according to the following schedule:

 

	 	(a)   Calendar Year 2013, payable January 1,2014	20,000
	 	(b)   Calendar Year 2014, payable January 1, 2015	40,000
	 	(c)   Calendar Year 2015, payable January 1, 2016	70,000
	 	(d)   Calendar Year 2016, payable January 1, 2017	100,000
	 	(e)   Calendar Year 2017, payable January 1, 2018	150,000
	 	(f)   Calendar Year 2018 (payable January I , 2019)	 
	 	and each year thereafter (payable each January 1st)	 
	 	through the expiration of this
    Agreement	$200,000

 

In the event that LICENSEE's payment of royalties for the Calendar
Year due under paragraph 3.2 do not meet or exceed the required minimum annual consideration, LICENSEE's royalty payment for the
last quarter of the Calendar Year must include payment of the balance needed to achieve the required minimum. If this Agreement
expires or is terminated before the end of a Calendar Year, the corresponding minimum annual consideration must be prorated for
that year.

 

		3.6	Milestone Payments. In order to maintain this license
to PATENT RIGHTS, LICENSEE must pay S&W milestone payments according to the following schedule:

 

		(a)	Upon successful conclusion of each Phase I clinical trial
for each Licensed Product/Indication: Milestone payment of one hundred thousand dollars ($100,000) or the amount paid by a SUBLICENSEE
per Article IV, Paragraph 4.2, whichever is higher.

 

 

    	4

    	 

    

 

		(b)	Upon successful conclusion of each Phase Ill clinical trial
or any other clinical trial following a Phase II clinical trial for each Licensed Product/indication: Milestone payment of five
hundred thousand dollars ($500,000) or the amount paid by a SUBLICENSEE per Article IV, Paragraph 4.2, whichever is higher.

 

		(c)	Upon each regulatory/market approval on each Licensed Product/indication:
Milestone payment of two million dollars ($2,000,000) or the amount paid by a SUBLICENSEE per Article IV, Paragraph 4.2, whichever
is higher.

 

ARTICLE IV -SUBLICENSES

 

		4.1	Sublicenses. LICENSEE may grant sublicenses to persons,
firms, or corporations under conditions consistent with this Agreement as long as each sublicense is not repugnant to the mission
of S&W or the public policies of SYSTEM, the State of Texas, or the United States.

 

		4.2	SUBLICENSEE Consideration. Sales of LICENSED PRODUCTS
by each SUBLICENSEE will be subject to the unit royalty due to S&W prescribed in paragraph 3.2. Further, LICENSEE must pay
S&W for other considerations not in the form of royalty received by LICENSEE from each sublicense for a grant of rights in
PATENT RIGHTS in accordance with the following Schedule 1:

 

Schedule 1

	Effective Date of Sublicense	Percentage of Other Sublicense Consideration due to S&W
	Within the first year of the Effective date of this Agreement	50%
	Within the second year of the Effective Date of this Agreement	35%
	Within the third year of the Effective Date of this Agreement	35%
	Any year following the third year of the Effective Date of this Agreement	20%

 

In the event that LICENSEE is required to pay a percentage
of Sublicense Consideration to one or more third parties in order to produce and/or sell the LICENSED PRODUCTS, the running
royalty rate prescribed above shall be reduced in accordance with the following Schedule 2:

 

Schedule 2

	Effective Date of Sublicense	Percentage of Other Sublicense Consideration due to third parties	Percentage of Other Sublicense Consideration due to SYSTEM	Percentage of Other Sublicense Consideration due to LICENSEE
	Within the first year of the Effective date of this Agreement	35%	15%	50%
	Within the second and third year of the Effective Date of this Agreement	20%	20%	60%
	Any year following the third year of the Effective Date of this Agreement	20%	15%	65%

 

Notwithstanding the foregoing, and as the only exception,
LICENSEE may not be required to remit to S&W any portion of funds it receives from any SUBLICENSEE(s) when the funds are
documented in writing as payments for the following purposes: (i) research, development, or testing of LICENSED PRODUCTS, or
(ii) patent expenses for protection of PATENT RIGHTS to which the SUBLICENSEE is contributing.

 

    	5

    	 

    

 

		4.3	Reporting. LICENSEE must notify S&W of the grant
of sublicense to a third party and must provide S&W with copies of each sublicense and of each SUBLICENSEE's report as is
pertinent to calculation of amounts due S&W under this Agreement.

 

		4.4	Non-Cash Transactions. LICENSEE may not accept anything
of value in lieu of money payment under a sublicense without the express written permission of S&W.

 

ARTICLE V - LICENSEE RESPONSIBILITIES

 

		5.1	Patent Expenses: Past Expenses and Future Costs.
Licensee is responsible for its documented expenses incurred prior to the EFFECTIVE DATE in the prosecution and maintenance of
PATENT RIGHTS, and will be directly responsible for such future expenses beyond the EFFECTIVE DATE as further described in Article
VI.

 

		5.2	Milestones. In accomplishing the commercialization
under this Agreement, LICENSEE must achieve the following milestones to the satisfaction of S&W:

 

		(a)	LICENSEE shall submit a Business Plan to S&W on or
before 9/18/13. The Business Plan must, at a minimum, include LICENSEE's plans for the development and commercialization of Licensed
Products, including milestones, summary of personnel, expenditures, anticipated market potential and timeline.

 

		(b)	LICENSEE shall submit annual diligence reports to S&W
that describe progress made in the progress of the research and development, evaluation, testing. regulatory approvals, manufacturing.
sublicensing, marketing, sales, and commercialization of any LICENSED PRODUCTS the most recent time period and plans for the forthcoming
year per each application or patent of the Patent Rights.

 

		(c)	LICENSEE must provide written notification to S&W within
thirty (30) days of achieving each milestone. Failure to meet a milestone constitutes a breach that if uncured within 120 days,
will result in removing the affected PATENT RIGHTS and PROPRIETARY INFORMATION, if any, from the Agreement.

 

		(d)	LICENSEE by itself or through its AFFILIATES and SUBLICENSEES
will use diligent efforts to make LICENSED PRODUCTS commercially available in accordance with the terms of the Agreement. Without
limiting the foregoing, LICENSEE will, itself or through one or more SUBLICENSEEs:

 

		(1)	maintain a bona fide, funded, ongoing and active research,
development, manufacturing, regulatory, marketing and/or sal es program (all as commercially reasonable) to make LICENSE PRODUCTS
commercially available to the public as soon as commercially practicable, and

 

		(2)	fulfill each of the following diligence milestones as set
forth in Table 3 by the deadlines indicated in Table 3:

 

 

    	6

    	 

    

 

Table 3

 

Diligence Milestones

1 . LICENSEE or a SUBLICENSEE at any Phase 1 clinical trial
for a Licensed Product/indication ·within 2 years of the effective date of the license agreement

 

2. A Phase II clinical trial for a Licensed Product/indication
within two years following completion of a Phase clinical trial license agreement, but subject to approval by S&W shall be
afforded more time if such is due to the nature of requirements met in Phase 1.

 

 

		5.3	Failure to Accomplish Milestones. Should LICENSEE
fail to achieve any milestone specified in paragraph 5.2, or should LICENSEE fail to record NET SALES for two (2) consecutive
Calendar Years once sales begin, S&W, at its sole option, may waive the requirement to achieve the milestone, reduce the license
granted to a nonexclusive license, renegotiate the missed milestone, or terminate this Agreement under paragraph 8.3.

 

		5.3	Legal Compliance. LICENSEE must comply with all
applicable federal, state and local laws and regulations in its exercise of all rights granted by S&W under this Agreement.

 

		5.4	U.S. Manufacture. To the extent that rights under
this Agreement are subject to rights required to be granted to the Government of the United States of America under 35 USC §§
200-212, LICENSED PRODUCTS must be manufactured substantially in the United States of America.

 

ARTICLE VI- PROTECTION OF INTELLECTUAL PROPERTY

 

		6.1	Authorization. As to prosecution, registration,
and/or protection of PATENT RIGHTS, S&W hereby authorizes LICENSEE to: 1) direct the preparation and filing of patent applications,
2) direct the prosecution of broad patent claims for the mutual benefit of LICENSEE, S&W, and SYSTEM, 3) maintain U.S. and
non-U.S. issued and granted patents, and 4) be invoiced directly by LICENSEE's outside patent counsel (as approved by S&W
under paragraph 6.2 herein) and/or annuity service providers for patent prosecution and associated maintenance fees and costs.
S&W may revoke this authorization at any time by giving ten (10) days written notice to LICENSEE.

 

		6.2	Selection of Counsel. LICENSEE may select an outside
patent counsel (Counsel) law firm staffed by experienced, reputable, and licensed intellectual property attorneys for the prosecution,
registration, protection, and maintenance of PATENT RIGHTS. LICENSEE will notify S&W of its selection of Counsel and S&W
will have final approval on such selection, and such approval shall not be unreasonably withheld.

 

		6.3	Contract with Counsel. LICENSEE shall execute a
written agreement with Counsel establishing that: 1) the attorney/client relationship relative to the prosecution, registration,
or protection of PATENT RIGHTS will be with S&W and LlCENSEE jointly; 2) Counsel will not take any actions adverse to the
interests of S&W in relation to PATENT RIGHTS including, for example and without limitation, any future invalidity or adverse
litigation actions; 3) costs for prosecution, registration, or protection of PATENT RIGHTS will be invoiced directly to LICENSEE
with a courtesy copy of the invoice lo S&W; and 4) S&W will not be responsible for payment of invoices relating to prosecution,
registration, or protection of PATENT RIGHTS conducted under this Agreement. including, without limitation, attorneys·
fees, costs, official filing fees, and foreign associates' fees and costs. LICENSEE shall provide a copy of such written agreement
to S&W. Additionally, LICENSEE shall ensure that Counsel promptly signs the standard Outside Counsel Agreement, which Counsel
can obtain from S&W's Office of General Counsel.

 

 

 

    	7

    	 

    

 

		6.4	Approvals. LICENSEE shall notify S&W before any substantive
actions are taken in prosecuting, continuing, or abandoning any patents or patent applications or otherwise affecting PATENT RIGHTS
and LICENSEE will instruct Counsel to so notify S&W. In addition to other substantive actions, LICENSEE agrees that S&W
will have final approval on the filing of any action or application that seeks to, or effects, changes in inventorship related
to PATENT RIGHTS, and will so instruct Counsel. LICENSEE agrees that S&W will have final approval on how to proceed with any
substantive actions relating to and/or affecting PATENT RIGHTS.

 

		6.5	Patent Maintenance. During the term of this Agreement,
LICENSEE shall be directly responsible for annual or periodic annuity payments to maintain the pendency of non-U.S. patent applications
in countries that require such annual or periodic annuities. Furthermore, during the term of this Agreement, LICENSEE agrees to
continue any required annual and periodic payments for maintenance of U.S. and non-U.S. issued and granted patents.

 

		6.6	Patent Maintenance Contract. LICENSEE shall engage
Counsel or a reputable annuity service to be responsible for docketing and payment of annual or periodic annuities and maintenance
fees for both U.S. and non-U.S. pending applications and U.S. and non-U.S. issued and granted patents during the term of this
Agreement.

 

		6.7	Advance Payment of Maintenance Fees. Should LICENSEE
request in writing that S&W direct payment of annuities and/or maintenance fees relating to PATENT RIGHTS, LICENSEE agrees
to provide payment of estimates for such annuities/fees ninety (90) days in advance of the due date. LICENSEE agrees that failure
to make such timely advance payments to S&\V shall be reasonably construed to be a decision to abandon such patent application
or patent and that S&W has full rights to determine whether or not to pay the annuity or maintenance fees with no further
obligation to LICENSEE. Furthermore, should S&W decide to continue maintenance of the patent application or patent at its
own expense, LICENSEE hereby agrees that any such application or patent will be excluded from PATENT RIGHTS.

 

		6.8	Confidential Communications. S&W and LICENSEE
have a community of interest with regard to work conducted in relation to PATENT RIGHTS due to their common interest in the generation
of enforceable Intellectual Property rights relating to LICENSED PRODUCTS and/or LICENSED SERVICES. Any communications between
LICENSEE and Counsel shall not be confidential vis a-vis S&W, but shall be otherwise confidential and protected by attorney
client privilege.

 

		6.9	Correspondence. LICENSEE shall contemporaneously
copy SYSTEM and S&W on all correspondence to and from any patent office, U.S. or non-U.S., including all periodic annuities
and maintenance fees correspondence, and LICENSEE agrees to so instruct Counsel to provide copies of such correspondence to SYSTEM
and S&W. LICENSEE further agrees that LICENSEE's failure to timely provide such correspondence will be considered a breach
of this Agreement in accordance with Paragraph 8.3 below.

 

		6.10	Information. To aid LICENSEE in the prosecution,
registration, protection, and maintenance of PATENT RIGHTS, S&W will provide information, execute and deliver documents, and
perform other acts as LICENSEE reasonably requests from time to time. LICENSEE will reimburse S&W for S&W's reasonable
costs incurred in complying with such requests.

 

		6.11	Abandonment. Should LICENSEE decide to abandon any
U.S. or non-U.S. parent application or issued or granted patent for commercial reasons or by declining to make an annuity or maintenance
payment. LICENSEE shall immediately notify S&W in writing, and S&W shall have the right to continue patent prosecution
or maintenance at its own expense and any such patent application and granted or issued patent there from will be excluded from
PATENT RIGHTS in this License Agreement.

 

 

    	8

    	 

    

 

		6.12	Assignee. All patent applications and patents related
to this Agreement shall have named as the assignee(s): ·"The Texas A&M University System" and/or "Scott
& White Healthcare", as appropriate.

 

		6.13	Obligation to File or Maintain. Should LICENSEE
decide not to file or maintain patent protection, S&W may. at its own expense, without reimbursement from LICENSEE, file,
prosecute, or maintain the patent protection and LICENSEE hereby agrees that any such patent will be excluded from the rights
granted herein.

 

ARTICLE VII- PAYMENTS AND REPORTS

 

		7.1	When Payments are Due. Unless otherwise specified,
LICENSEE must make payments to Scott & White Healthcare, in Temple, Texas, not later than sixty (60) days after the last day
of the calendar quarter in which they accrue.

 

		7.2	Royalty Reports. Beginning the first quarter in
which Net Sales occurs or sublicensing income is received, LICENSEE must provide a sales report to &W each calendar quarter,
providing information sufficient to allow S&W to calculate amounts due S&W for the reporting period.

 

		7.3	Currency. Payment due to S&W must be paid in
U.S. dollars. Royalty payments requiring conversion must use the exchange rate as reported in The Wall Street Journal on the last
business day of the royalty reporting period.

 

		7.4	Inspection of Books and Records. At its own expense,
S&W may annually inspect LICENSEE's books and records as needed to determine royalties payable. LICENSEE must maintain those
books and records for at least three years following the dates of the underlying transactions. Any inspections will be in confidence
and conducted during ordinary business hours, and S&W will provide LICENSEE advance notice two weeks before making an inspection.
S&W may employ a Certified Public Accountant for this purpose. lf S&W's audit identities a shortage of five percent (5%)
or more of amounts due to S&W, then LICENSEE must pay the costs of S&W's audit. LICENSEE must pay all amounts due as a
consequence of an audit to S&W promptly, with interest.

 

		7.5	Interest Charges. S&W may, in its sole discretion,
charge daily interest on overdue payments commencing on the 31st day after the payment is due, compounded monthly, at the lower
of either one and a half percent (1.5%) per month or the highest legal interest rate. The payment of interest will not foreclose
S&W from exercising any other rights it may have due to the lateness of any payment.

 

ARTICLE VIII - TERM AND TERMINATION

 

		8.1	Expiration. This Agreement, unless sooner terminated
as provided below, will remain in effect until (a) expiration or the last to expire patent under PATENT RIGHTS, or (b) final and
unappealable determination by a court of competent jurisdiction that PATENT RIGHTS are invalid.

 

		8.2	Termination by LICENSEE. LICENSEE may terminate
this Agreement by providing written notice to S&W at least ninety (90) days before the termination is to take effect.

 

 

    	9

    	 

    

 

		8.3	Termination by S&W. lf LICENSEE materially breaches
this Agreement, S&W may give LICENSEE written notice of the breach. LICENSEE will have sixty (60) days from receipt of the
notice to cure the breach. lf LICENSEE does not cure the breach within this period, S&W may terminate this Agreement without
further notice.

 

		8.4	Matters Surviving Termination. All accrued obligations
and claims, including license fee obligations, royalty obligations. minimum annual consideration obligations, interest charge
obligations, and all other financial obligations, and claims or causes of action for breach of this Agreement, will survive termination
of this Agreement. Obligations of confidentiality will survive termination of this Agreement This section controls in the case
of a conflict with any other section of this Agreement.

 

ARTICLE IX - INDEMNIFICATION AND REPRESENTATION

 

		9.1	Indemnification. LICENSEE MUST AT ALL TIMES DURING
AND AFTER THE TERM OF THIS AGREEMENT INDEMNIFY, DEFEND, AND HOLD HARMLESS SYSTEM AND S&W, ITS REGENTS, OFFICERS, BOARD MEMBERS,
AND CURRENT AND FORMER EMPLOYEES AGAINST ANY CLAIM, PROCEEDING, DEMAND, LIABILITY OR EXPENSE (INCLUDING LEGAL EXPENSE AND REASONABLE
ATTORNEY'S FEES) WHICH RELATES TO INJURY TO PERSONS OR PROPERTY, ANY ACTION BROUGHT BY A THIRD PARTY ALLEGING INFRINGEMENT OF
INTELLECTUAL PROPERTY RIGHTS, OR AGAINST ANY OTHER CLAIM, PROCEEDING, DEMAND, EXPENSE, OR LIABILITY OF ANY KIND RESULTING FROM
TH PRODUCTION, MANUFACTURE, SALE, COMMERCIAL USE, LEASE, CONSUMPTION, OR ADVERTISEMENT OF LICENSED PRODUCTS OR ARISING FROM ANY
OBLIGATION OF LICENSEE OR SUBLICENSEE(S) UNDER THIS AGREEMENT.

 

		9.2	Representation. S&W represents that it owns
and has title to, either solely, jointly with SYSTEM, or jointly with SYSTEM and LICENSEE, PATENT RIGHTS and has the full right
and power to grant the license in paragraph 2.1, and that there are no outstanding agreements, assignments, or encumbrances inconsistent
with the provisions of this Agreement. S&W MAKES NO OTHER REPRESENTATIONS AND EXTENDS NO OTHER WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, NOR DOES S&W
ASSUME ANY OBLIGATION REGARDING INFRINGEMENT OF PATENT RIGHTS OR OTHER RIGHTS OF THIRD PARTIES DUE TO LICENSEE'S ACTIVITIES UNDER
THIS AGREEMENT.

 

ARTICLE X - NOTICES

 

		10.1	Notices. Payments, notices, or other communications
required by this Agreement will be sufficiently made or given if mailed by certified First Class United States mail, postage pre-paid,
or by commercial carrier (e.g.. FedEx, UPS, etc.) when the carrier maintains receipt or record of delivery, addressed 10 the address
stated below, or to the last address specified in writing by the intended recipient.

 

 

    	10

    	 

    

 

If to S&W:

 

Contact for Payments/Accounting:

Attn: Linda M. Burke

AVP - Academic Finance

Scott & White Healthcare

2401 South 3151 Street

MS- AR-M113

Temple, TX 76508

Phone: 254-724-5093

Fax: 254-215-9275

(Please reference Patent License Agreement Number SW11l-003PLA

 

Contact for all other communications:

 

Monica A. De La Paz, M.D.

Vice President, Intellectual Properties

Office of General Counsel

Scott & White Healthcare

MS-20-D642

2401 South 31st Street

Temple, Texas 76508

Phone: 254-724-7213

Fax: 254.724.5492

Email:mdelapaz@sw.org

(Please reference Patent License Agreement Number SW11-003PLA

 

If to LICENSEE

 

Contact for notice:

 

Robert Berliner

Berliner & Associates

555 West Fifth Street

31st Floor

Los Angeles, CA 90013

tel: 213-533-4171

fax:213-533-4174

rberliner@berliner-ip.com

 

Contact for all other matters:

 

Haig Keledjian, President

VG Life Sciences, Inc.

2290 Huntington Drive Suite 100

San Marino, California, USA 91108

Phone: 626-334-5310

FAX: 626-334-5224

Email: haig@viralgenetics.com

 

	If to SYSTEM:	Associate Vice Chancellor
	 	Office of Technology Commercialization
	 	800 Raymond Stotzer Parkway; Suite 2020
	 	College Station, Texas, USA 77845

 

 

    	11

    	 

    

 

 

ARTICLE XI- PATENT INFRINGEMENT

 

		11.1	Notice of Infringement. Each Party must promptly
notify the other in writing of any alleged infringement of PATENT RIGHTS that comes to its attention. Within sixty (60) days after
receipt of such notice, S&W and LICENSEE will formulate a strategy for resolving the alleged infringement.

 

		11.2	LICENSEE Right to Bring Suit. Following the initial
sixty (60) day strategy period pursuant to Paragraph 11.1, LICENSEE may institute suit for patent infringement against the infringer.
SYSTEM and/or S&W may voluntarily join such suit at their own expense. but may not thereafter commence suit against the infringer
for the acts of infringement that are the subject of the LICENSEE's suit or any judgment rendered in that suit. LICENSEE may join
S&W as a party in a suit initiated by LICENSEE if S&W is a necessary party to the law suit under the procedural rules
of the applicable jurisdiction. If S&W is involuntarily joined other than by the voluntary action of S&W or is joined
as a necessary party as a matter of law, then LICENSEE will pay any costs incurred by S&W arising out of such suit, including
but not limited to, any legal fees of the counsel that S&W selects and retains to represent it in the suit; provided, however,
that S&W shall endeavor to retain the same counsel as LICENSEE i n the same lawsuit subject to potential conflict of interests.

 

		11.3	S&W Right to Bring Suit. If, within a hundred
and ninety (90) days following the notice of infringement, LICENSEE has not brought suit against the infringer pursuant to Paragraph
11.2, then SYSTEM and/or S&W may institute suit for patent infringement against the infringer. If SYSTEM and/or S&W institutes
such suit, then LICENSEE may not join such suit without SYSTEM's or S&W's consent and may not thereafter commence suit against
the infringer for the acts of infringement that are the subject of SYSTEM's and/or S&W's suit or any judgment rendered in
that suit.

 

		11.4	Control of Litigation. Any litigation proceedings
will be controlled by the party bringing the suit.

 

		11.5	Recovery. Any recovery or settlement received in
connection with any suit will first be shared by S&W and LICENSEE to cover any litigation costs each incurred, in proportion
to their respective costs. In any suit initiated by LICENSEE pursuant to Paragraph 11.2, any recovery in excess of litigation
costs will be shared between LICENSEE and S&W as follows: (a) for any recovery other than amounts paid for willful infringement
or as punitive damages LICENSEE shall receive an amount equal to its lost profits or a reasonable royalty on the infringing sales,
or whichever measure of damages the court shall have applied, and LICENSEE shall pay to S&W a portion of its recovery a reasonable
approximation of the royalties and other amounts that LICENSEE would have paid to S&W if LICENSEE bad sold the infringing
products, processes and services rather than the infringer, and (b) as to amounts paid for willful infringement or as punitive
damages, SYSTEM will receive thirty percent (30%) of the recovery if S&W was not a party in the litigation and did nor incur
any litigation costs that were not reimbursed by LICENSEE or fifty percent (50%) of the recovery if SYSTEM was a party in the
litigation whether joined as a party under the provisions of Paragraph 11.2 or voluntarily. In any suit initiated by SYSTEM and/or
S&W pursuant to Paragraph 11.4, any recovery in excess of litigation costs will belong to SYSTEM and/or S&W.

 

    	12

    	 

    

 

 

ARTICLE XI - MISCELLANEOUS PROVISIONS

 

		12.1	Export Controls. S&W and SYSTEM are subject
to United States laws and regulations controlling the export of technical data, computer software laboratory prototypes and other
commodities, and its obligations under this Agreement arc contingent on compliance with applicable laws and regulations. The transfer
of certain technical data and commodities may require a license from the cognizant agency of the United States Government or written
assurances by LICENSEE that LICENSEE will not export data or commodities to certain countries without advance approval of such
agency. S&W neither represents that a license will not be required nor that, if required, it will be issued.

 

		12.2	Confidential Information. Sales reports submitted
by LICENSEE under ARTICLE VII will be considered Confidential Information under this Agreement and not be disclosed by S&W
to any third party except as may be required by law. If the Parties contemplate exchanging other information of a confidential
nature, they should enter into a separate confidentiality agreement.

 

		12.3	Non-Use of Names. LICENSEE may not use the names
or any adaptation of the names of Scott & White Healthcare or SYSTEM, nor of any of its employees or members, in any advertising,
promotional, or sales literature without the advance written consent of S&W and/or SYSTEM in each case, except that LICENSEE
may state that it is licensed by S&W under PATENT RIGHTS.

 

		12.4	Trademarks. LICENSEE may select, own and use its
own trademark on LICENSED PRODUCTS. However, S&W does not grant LICENSEE any license or other right under any trade name,
trademark or service mark owned or licensed by S&W or SYSTEM. Conversely, S&W has no rights to trade names, trademarks,
or service marks owned by LICENSEE.

 

		12.5	Assignment of this Agreement. This Agreement, with
the rights and privileges it creates, 1s assignable only with the written consent of both Parties.

 

		12.6	Force Majeure. Other than an obligation for the
payment of money, S&W, upon receipt of documentation from LICENSEE which it deems appropriate, must excuse any breach of this
Agreement which is proximately caused by war, strike, act of God, or other similar circumstance normally deemed outside the control
of well-managed businesses.

 

		12.7	Entire Agreement. This Agreement contains the entire
understanding of the Parties regarding PATENT RIGHTS, and supersedes all other written and oral agreements between the Parties
regarding PATENT RIGHTS. It may be modified only by a written amendment signed by the Parties.

 

		12.8	Governing Law. The substantive Laws of the State
of Texas (and not its conflicts of law principles), USA, govern all matters arising out of or relating to this Agreement and all
of the transactions it contemplates. Venue for any suit brought against S&W in Texas state court must be in Bell County, Texas,
and venue for any suit brought against S&W in federal court must be in Texas.

 

		12.9	Headings. Headings are solely for convenience of
reference and are not part of, and may not be used to construe, this Agreement.

 

		12.10	No Waiver; Severability. If any provision of this
Agreement is invalid, illegal, or unenforceable, the validity, legality and enforceability of the remaining provisions will not
not in any way be affected or impaired. A waiver of any breach of this Agreement does not waive any other breach of the same or
other provision of this Agreement. A waiver is not effective unless made in writing.

 

 

    	13

    	 

    

 

		12.11	Counterparts. This agreement may be executed in
any number of counterparts, including facsimile or scanned PDF documents. Each such counterpart, facsimile, or scanned PDF document
shall be deemed an original instrument, and all of which, together, shall constitute one and the same executed Agreement.

 

		12.12	No Other Promises and Agreements; Representation by
Counsel. Licensee expressly certifies and represents that no promise or agreement which is not herein expressed has been made
to Licensee in executing this Agreement except those explicitly set forth herein and that Licensee is not relying upon any statement
or representation of Licensor or its representatives. Licensee is relying on Licensee's own judgment and has had the opportunity
to be represented by legal counsel. Licensee hereby warrants and represents that Licensee understand and agrees to all terms and
conditions set forth in this Agreement.

 

		12.13	Deadline for Execution by Licensee. If this Agreement
is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the manner
set forth in paragraph 10.1 of the Agreement within 30 days of the date of signature set forth under the Licensor's signature
below, then this Agreement shall be null and void and of no further effect.

 

The Parties have caused this Agreement to become effective as
of the date last executed below.

 

	LICENSEE: VG LIFE SCIENCES, INC.	 	LICENSOR: SCOTT & WHITE HEALTHCARE
	 	 	 
	 	 	 
	/s/ Haig Keledjian	 	/s/ Robert W. Pryor
	By: Haig Keledjian	 	Robert W. Pryor, M.D.
	Title: President	 	President/CEO
	 	 	 
	Date: 7/6/2013	 	Date: 7/18/2013

 

 

    	14Exhibit 10.116

 

SUBSCRIPTION AGREEMENT

 

VG LIFE SCIENCES, INC.

121 Gray Avenue, Suite 200

Santa Barbara, CA 93101

 

THE COMMON STOCK OF VG
LIFE SCIENCES INC., INCLUDING THAT ACQUIRABLE UPON EXCHANGE OF THE CONVERTIBLE DEBENTURE, DESCRIBED IN THIS SUBSCRIPTION AGREEMENT
(this "Agreement") HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("Act"), OR QUALIFIED
UNDER THE STATE SECURITIES LAWS OF ANY STATE. THE SECURITIES ARE BEING SOLD IN RELIANCE ON EXEMPTIONS FROM SUCH REGISTRATION AND
QUALIFICATION REQUIREMENTS. THE SECURITIES AND RIGHTS PURSUANT TO THIS AGREEMENT CANNOT BE SOLD, TRANSFERRED, ASSIGNED, OR OTHERWISE
DISPOSED OF, EXCEPT IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS, INCLUDING REGULATION S PROMULGATED UNDER THE
ACT.

 

ALL OFFERS AND SALE
OF SAID SECURITIES BY NON-U.S. PERSONS PRIOR TO THE EXPIRATION OF A PERIOD COMMENCING ON THE DATE OF THE CLOSING OF THIS OFFERING
AND ENDING ONE-YEAR THEREAFTER SHALL ONLY BE MADE IN COMPLIANCE WITH THE SAFE HARBOR CONTAINED IN REGULATION S, PURSUANT TO THE
REGISTRATION PROVISIONS UNDER THE SECURITIES ACT OF 1933, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION, AND ALL OFFERS AND SALES
AFTER THE EXPIRATION OF THE ONE-YEAR PERIOD SHALL BE MADE ONLY PURSUANT TO REGISTRATION OR AN EXEMPTION FROM REGISTRATION.

 

This Agreement shall constitute
the irrevocable offer of the undersigned to purchase, in the amounts and subject to the terms set forth in this Agreement, one
Convertible Debenture of VG Life Sciences Inc., a Delaware corporation (the "Company") ("Debenture"), with
the face value of $_____in the form attached hereto as Exhibit A, for the purchase price of $_____. On execution by both parties,
this Agreement shall become a bilateral agreement binding on both the undersigned and the Company. Each part of this Agreement
must be completed by the undersigned and, by execution below, the undersigned acknowledges that it understands that the Company
is relying on the accuracy and completeness hereof in complying with its obligations under applicable securities laws.

 

On the foregoing,
it is hereby agreed as follows:

 

1.SUBSCRIPTION. The undersigned hereby irrevocably subscribes
for the purchase of the Debenture. The undersigned is tendering to the Company:

 

(a)                                       
one signed copy of this Agreement; and

 

(b)                                      
payment in the amount of $5,000 (the "Purchase Price").

 

2.GENERAL REPRESENTATIONS OF SUBSCRIBER. The undersigned
hereby represents and warrants as follows:

 

(a)The undersigned is over the age of 18 years;

 

    	1

    	 

    

 

 

(b)The
undersigned acknowledges that neither the United States Securities and Exchange Commission nor the securities commission of any
state or other federal agency has made any determination as to the merits of purchasing these securities;

 

(c)The undersigned
has received and read all of the Company's filings made on the OTCIQ News and Disclosure system and available at
www.pinksheets.com including the "Quarterly Report" and "Consolidated
Financial Statements" for the three months ended March 30, 2013; the "Annual Report" and "Consolidated Financial
Statements" for the fiscal year ended December 31, 2011 and December 31, 2012; the "Initial Company Information and Disclosure
Statements" for the nine months and three months ending September 30, 2009 and March 31, 2009, respectively; the "Articles
of Incorporation — Amendment" filed May 15, 2009; and the "Supplemental Information — Current Reporting Obligations
Filing — Merger" filed April 24, 2009; as well as all prior filings made on the SEC EDGAR system including, without
limitation, the Form 10- KSB, as amended, for the fiscal year ended December 31, 2006, the Quarterly Report on Form 10-QSB for
the quarter ended September 30, 2007, all Current Reports on Form 8-K, all other filings and disclosures made on the OTCIQ News
and Disclosure system and available at www.Pinksheets.com
all press releases, and other information; and the undersigned understands the risk of an investment in the Company, acknowledging
that an investment in the Company inherently involves high risks.

 

(d)The undersigned,
either alone or with the assistance of one or more advisers engaged by it, has such knowledge and experience in business and financial
matters that it or they is capable of evaluating the Company, its business operations, and the risks and merits of an investment
in the Company;

 

(e)The undersigned
has been provided with all materials and information requested by the undersigned or its representatives, including any information
requested to verify any information furnished, and the undersigned has been provided the opportunity for direct communication between
the Company and its representatives and the undersigned and its representatives regarding the purchase made hereby, including the
opportunity to ask questions of and receive answers from the Company including with regards to any of the information described
in 2 (c) above;

 

(f)All information
which the undersigned has provided to the Company or its agents or representatives concerning the undersigned's suitability to
invest in the Company is complete, accurate, and correct as of the date of the undersigned's signature on this Agreement. Such
information includes, but is not limited to, information concerning the undersigned's personal financial affairs, business position,
and the knowledge and experience of the undersigned and the undersigned's advisers;

 

(g)The undersigned
has no present intention of dividing any of the securities or the rights under this Agreement with others or of reselling or otherwise
disposing of any portion of the securities, either currently or after the passage of a fixed or determinable period of time or
on the occurrence or nonoccurrence of any predetermined event or circumstance;

 

(h)The undersigned
was at no time solicited by any leaflet, public promotional meeting, circular, newspaper or magazine article, radio or television
advertisement, or any other form of general advertising or solicitation in connection with the offer, sale, or purchase of the
securities through this Agreement; and

 

(i)The undersigned
has adequate means of providing for its current needs and possible contingencies and has no need now and anticipates no need in
the foreseeable future, to sell any portion of the securities for which the undersigned hereby subscribes. The undersigned is able
to bear the economic risks of this investment and, consequently, without limiting the generality of the foregoing, is able to hold
the securities for an indefinite period of time, and has a sufficient net worth to sustain a loss of the entire investment, in
the event such loss should occur.

 

    	2

    	 

    

 

(j)The
undersigned is an Accredited Investor, and has completed the following Accredited Investor Qualifying Questionnaire:

 

PERSONAL FINANCIAL INFORMATION. The following information
pertaining to the undersigned as a natural person and U.S. Persons within the meaning of Regulation S is being provided
here in lieu of furnishing a personal financial statement.

 

(a)My individual net worth, or joint net
worth with my spouse, excluding any primary residence, exceeds $1,000,000.

 

 

__________                                   Yes
[X]       No [  ]

INITIAL

 

(b)My individual
income in 2011 and 2012 exceeded $200,000 in each such year, and I reasonably expect my individual income will be in excess of $200,000 in 2013.

 

__________                                   Yes
[X]       No [  ]

INITIAL

 

(c)The joint
income of my spouse and I in 2011 and 2012 exceeded $300,000 in each such year, and I reasonably expect our joint income will be
in excess of $300,000 in 2013.

 

__________                                   Yes
[X]       No [  ]

INITIAL

 

(d)Considering
the foregoing and all other relevant factors in my financial and personal circumstances, I am able to bear the economic risk
of an investment in the Company.

 

__________                                   Yes
[X]       No [  ]

INITIAL

 

 

3.REPRESENTATIONS
REGARDING EXEMPTIONS AND RESTRICTIONS ON TRANSFER. The undersigned represents that the securities are being acquired without
a view to, or for, resale in connection with any distribution of the securities or any interest therein without registration or
other compliance under the Act, and that the undersigned has no direct or indirect participation in any such undertaking or in
the underwriting of such an undertaking. The undersigned understands that the securities have not been registered, but are being
acquired by reason of a specific exemption under the Act as well as under certain state statutes for transactions by an issuer
not involving any public offering and that any disposition of the securities may, under certain circumstances, be inconsistent
with this exemption and may make the undersigned an "underwriter" within the meaning of the Act. The undersigned acknowledges
that the securities must be held and may not be sold, transferred, or otherwise disposed of for value unless they are subsequently
registered under the Act or an exemption from such registration is available. The Company is under no obligation to register the
securities under the Act or under Section 12 of the Securities Exchange Act of 1934, as amended. The certificates representing
the securities will bear a legend restricting transfer, except in compliance with applicable federal and state securities statutes.

 

4.GENERAL.
The undersigned further understands, acknowledges, and agrees that:

 

    	3

    	 

    

 

(a)This
Agreement is registered in the name of the undersigned on the books of the Company at its principal offices, and no transfer hereof
shall be valid and binding on the Company unless made at such offices by the registered holder or his attorney-in-fact duly authorized
in writing. The Company may deem and treat the person in whose name this Agreement is registered as the absolute owner hereof for
the purpose of receiving any securities issuable pursuant hereto and for all other purposes.

 

(b)This Agreement shall be construed in
accordance with and governed by the laws of the state of California.

 

(c)This Agreement constitutes the entire
agreement between the parties respecting the subject matter hereof.

 

(d)Notwithstanding any of the representations,
warranties, acknowledgments, or agreements made herein by the undersigned, the undersigned does not waive any rights granted to
the undersigned under federal and state securities laws.

 

(e)The undersigned will hold title to the
securities as follows:

 

_________________Community Property

 

_________________Joint Tenants, with Right
of Survivorship

 

_________________Tenants in Common

 

_________________Separate Property

 

 

______X________ Other      Single
Person

                                                     (Single
Person, Trust, Etc., Please Indicate)

 

    	4

    	 

    

 

 

DATED this 25th day
of August 2013.

 

	__________	/s/ Rodney Williams
	Tax
Identification Number or 

Social Security Number

	Type
or Print Name of Subscriber(s) in exact

 Form to be Used on Records of the Company

	 	 
	Address:	 
	 	 
	1080 Via Malibu	/s/[illegible]
	Number and Street	 
	 	 
	 	 
	Aptos, CA 95003	_______________________
	City, State and Postal Code	Signature of Joint Subscriber, If Any
	 	 
	 	 
	USA	Date: ______________________
	Country	 

 

 

 

ACCEPTANCE OF SUBSCRIPTION

 

The foregoing is
hereby accepted this _____ day of ______________, 2013.

 

	 	VG LIFE SCIENCES INC.
	 	 
	 	_________________________________
	 	By: __________________________
	 	Its: _________________________

 

 

    	5

    	 

    

 

EXHIBIT A

 

NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT. THIS DEBENTURE DOES NOT REQUIRE PHYSICAL SURRENDER HEREOF IN ORDER TO EFFECT A PARTIAL PAYMENT, REDEMPTION OR CONVERSION HEREOF.
ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS DEBENTURE MAY BE LESS THAN THE PRINCIPAL AMOUNT SHOWN BELOW.

 

VG LIFE SCIENCES INC.

 

0%UNSECURED CONVERTIBLE DEBENTURE

 

	Santa Barbara, California	$5,000

 

Issue Date: _____________________2013

 

FOR VALUE RECEIVED,
VG LIFE SCIENCES INC., a Delaware corporation (the "Company"), hereby promises to pay to the order
of Rodney Wiliams or their permitted successors or assigns (the "Holder")
the sum of ___________ thousand dollars ($________) in same day funds, on or before the one-year anniversary of the date
of issue specified above (the "Maturity Date") together with accrued interest of the simple rate of two
percent (2%) per annum, as specified herein.. The Company's obligations under the Debenture, including without limitation its obligation
to make payments of principal thereof and interest thereon, are unsecured.

 

The following terms shall apply to this Debenture:

 

1. DEFINITIONS.

 

"Conversion Price" means
a 10% discount to the lowest 3 day average closing price starting on July 16th, 2013 and ending September 15, 2013.
Additionally, Conversion includes warrant coverage at $1.00 . The warrant to Shares in the form attached hereto as Exhibit B
(the "Warrants") and have a term of 12 months beginning on the date of this unsecured convertible debenture.

 

"Default Interest Rate" means Zero (%).

 

"Issue Date"
means the date on which this Debenture is issued, which shall be the date cash funds are received by the Company for the
Purchase Price pursuant to the Subscription Agreement that this Debenture was acquired under.

 

"Maturity Date" has
the meaning set forth in the preamble to this Agreement.

 

 

    	6

    	 

    

 

"Person"
means any individual, corporation, trust, association, company, partnership, joint venture, limited liability company,
joint stock company, governmental authority or other entity.

 

All definitions contained
in this Debenture are equally applicable to the singular and plural forms of the terms defined. The words "hereof", "herein"
and "hereunder" and words of similar import referring to this Debenture refer to this Debenture as a whole and not to
any particular provision of this Debenture.

 

2.PAYMENT.

 

(a)Principal Payment.
The Company shall pay to the Holder, in cash on or before the Maturity Date, the original unpaid principal amount of this Debenture
(plus unpaid accrued interest thereon); provided, that if the Maturity Date is not a business day, such payment shall be
made on the next succeeding business day. The Principal Payment that is due in cash and which is not paid on the Maturity Date
shall bear interest until paid at the Default Interest Rate.

 

(b)Interest. This
Debenture shall bear interest at the simple annual rate of two percent (2%) calculated on the basis of a year of 365/366 days,
unless in Default, all due at the Maturity Date.

 

(c)Prepayment.
The Company may prepay the unpaid principal of this Debenture in whole or in part at any time by delivery in immediately-available
cash following 20 business days advance notice in writing.

 

3.CONVERSION.

 

(a)Conversion.
Subject to the conditions and limitations specifically provided herein, Holder may elect to exchange all or any part of unpaid
principal and interest into Shares (a "Conversion").

 

(b)Conversion Notice.
In order to effect a conversion of principal and accrued interest of this Debenture, the Holder shall send to Company by facsimile
transmission or email, at any time prior to 5:00 p.m., Pacific Time, on the business day on which the Company wishes to effect
such Conversion (the "Conversion Date"), a properly completed notice of conversion, in the form set forth
on Annex I hereto, stating the amount of principal (and, if the Holder so elects, Interest) to be converted and a calculation
of the number of Shares issuable upon such Conversion (a "Conversion Notice"). The Holder may specify the
name or names (if not the Holder) in which the Shares that are issuable on such Conversion shall be issued by notifying Company.
The Holder shall not be required to physically surrender this Debenture to the Company in order to effect a Conversion, unless
such Conversion would represent payment in full of the Debenture. The Company shall maintain a record showing, at any given time,
the unpaid principal amount of this Debenture and the date of each Conversion or other payment of principal hereof.

 

(c)Number of Shares; Conversion Price.
The number of Shares to be delivered by the Company pursuant to a Conversion shall be equal to the principal amount of (and, if
the Holder so elects, Interest accrued on) this Debenture being converted divided by the Conversion Price.
The Conversion Price shall be proportionately adjusted for any forward or reverse stock split, recapitalization, or other similar
change to common stock properties.

 

    	7

    	 

    

 

(d)Delivery of Common Stock Upon Conversion. Upon delivery
of a Conversion Notice, the Company shall, no later than the close of business on the fifteenth (15th) business day
following the Conversion Date set forth in such Conversion Notice (the "Delivery Date"), issue and deliver
or cause to be delivered to the Holder the number of shares of common stock ("Shares") determined pursuant
to paragraph 3(c) above. The Company shall effect delivery of the Shares to the Holder no later than the close of business on such
Delivery Date by delivering to the Holder or its nominee physical certificates representing such shares. If any Conversion would
create a fractional share, such fractional share shall be disregarded and the number of shares issuable upon such Conversion, in
the aggregate, shall be the nearest whole number.

 

4. MISCELLANEOUS.

 

(a)Failure to Exercise
Rights not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any
other or further exercise thereof. All rights and remedies of the Holder hereunder are cumulative and not exclusive of any rights
or remedies otherwise available.

(b)Notices. Any
notice, demand or request required or permitted to be given by the Company or the Holder pursuant to the terms of this Debenture
shall be in writing and shall be deemed delivered (i) when delivered personally or by verifiable facsimile transmission, unless
such delivery is made on a day that is not a business day, in which case such delivery will be deemed to be made on the next succeeding
business day and (ii) on the next business day after timely delivery to an overnight courier, addressed as follows:

 

If to the Company:

 

VG Life Sciences Inc.

121 Gray Avenue, Suite

200 Santa Barbara, CA 93101

Attn: Caleb Rhoads, Controller

Tel: 805-679-6711

Fax: 805-679-6711

 

If to the Holder:

 

______________

______________

Tel:________

Fax:__________

 

(c)Amendments. No amendment, modification
or other change to, or waiver of any provision of, this Debenture may be made unless such amendment, modification or change is
set forth in writing and is signed by the Company and the Holder.

 

 

    	8

    	 

    

 

(d)Transfer
of Debenture. The Holder may sell, transfer or otherwise dispose of all or any part of this Debenture (including without limitation
pursuant to a pledge) to any person or entity as long as such sale, transfer or disposition is the subject of an effective registration
statement under the Securities Act and applicable state securities laws, or is exempt from registration thereunder. From and after
the date of any such sale, transfer or disposition, the transferee hereof shall be deemed to be the holder of a Debenture in the
principal amount acquired by such transferee, and the Company shall, as promptly as practicable, issue and deliver to such transferee
a new Debenture identical in all respects to this Debenture, in the name of such transferee. The Company shall be entitled to treat
the original Holder as the holder of this entire Debenture unless and until it receives written notice of the sale, transfer or
disposition hereof.

 

(e)Lost or Stolen
Debenture. Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Debenture, and (in
the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and
cancellation of the Debenture, if mutilated, the Company shall execute and deliver to the Holder a new Debenture identical in all
respects to this Debenture.

(f)Governing Law.
This Debenture shall be governed by and construed in accordance with the laws of the State of California applicable to contracts
made and to be performed entirely within the State of California.

 

(g)Successors and
Assigns. The terms and conditions of this Debenture shall inure to the benefit of and be binding upon the respective successors
(whether by merger or otherwise) and permitted assigns of the Company and the Holder. The Company may not assign its rights or
obligations under this Debenture except as specifically required or permitted pursuant to the terms hereof.

 

(h)Usury. This
Debenture is subject to the express condition that at no time shall the Company be obligated or required to pay interest hereunder
at a rate which could subject the Holder to either civil or criminal liability as a result of being in excess of the maximum interest
rate which the Company is permitted by applicable law to contract or agree to pay. If by the terms of this Debenture, the Company
is at any time required or obligated to pay interest hereunder at a rate in excess of such maximum rate, the rate of interest under
this Debenture shall be deemed to be immediately reduced to such maximum rate and the interest payable shall be computed at such
maximum rate and all prior interest payments in excess of such maximum rate shall be applied and shall be deemed to have been payments
in reduction of the principal balance of this Debenture.

 

IN WITNESS WHEREOF, the
Parties have caused this Debenture to be signed in their name by a duly authorized officer on the date first above written.

 

VG LIFE SCIENCES INC.

 

By: _________________

Name:

Its:

    	9

    	 

    

 

ANNEX I

 

NOTICE OF CONVERSION

 

The Holder hereby elects to require conversion
of principal of and/or interest accrued on the 0% Unsecured Convertible Debenture (the "Debenture") into shares of common
stock ("Shares") of the Company according to the terms and conditions of the Debenture. Capitalized terms used herein
and not otherwise defined shall have the respective meanings set forth in the Debenture.

 

 

	 	 Date of Conversion:_________________________

 

Principal Amount of

Debenture to be Converted:_____________________

 

Amount
of Interest

to be Converted:______________________________

 

Number of Shares of

Common Stock to be Issued:_____________________

 

Name of Holder:_______________________________

 

Address: _________________

___________________

__________________

 

Signature: ________________

Name:

Title:

 

 

    	10

    	 

    

 

Exhibit
B

 

VIRAL GENETICS, INC.

 

Warrant for the Purchase of 

Shares of Common Stock 

Par Value $0.0001

 

WARRANT AGREEMENT

 

THE HOLDER OF THIS WARRANT, BY ACCEPTANCE
HEREOF, BOTH WITH RESPECT TO THE WARRANT AND COMMON STOCK ISSUABLE UPON EXERCISE OF THE WARRANT, AGREES AND ACKNOWLEDGES THAT THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE TRANSFERRED
OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR OTHER COMPLIANCE UNDER THE SECURITIES ACT OR THE LAWS OF THE APPLICABLE
STATE OR A "NO ACTION" OR INTERPRETIVE LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO THE ISSUER, AND ITS COUNSEL, TO THE EFFECT THAT THE SALE OR TRANSFER IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES
ACT AND SUCH STATE STATUTES.

 

This is to certify that, for value received, _____ (the "Holder")
is entitled to purchase from VIRAL GENETICS, INC., a Delaware corporation (the "Company"), on the terms and conditions
hereinafter set forth, all or any part of_____shares ("Warrant Shares") of the Company's common stock, par value $0.0001
(the "Common Stock"), at the purchase price of _____per share Warrant Shares ("Warrant Price"). Upon exercise
of this warrant in whole or in part, a certificate for the Warrant Shares so purchased shall be issued and delivered to the Holder.
If less than the total warrant is exercised, a new warrant of similar tenor shall be issued for the unexercised portion of this
warrant. By acceptance hereof, the Holder agrees to be bound by the terms and conditions of this warrant.

 

This warrant is granted subject to the following further terms and
conditions:

 

	1		This warrant shall vest and be exercisable immediately, and shall expire at 5:00 pm
Pacific Time one-year from the date of this agreement as stated below. In order to exercise this warrant with respect to all or
any part of the Warrant Shares for which this warrant is at the time exercisable, Holder must take the following actions:

 

	(a)		Deliver to the Corporate Secretary of the Corporation an executed notice of exercise
in substantially the form of notice attached to this Agreement (the "Exercise Notice") in which there is specified the
number of Warrant Shares that are to be purchased under the exercised warrant.

 

	(b)		Furnish to the Corporation appropriate documentation that the person or persons exercising
the warrant (if other than Holder) have the right to exercise this warrant.

 

    	11

    	 

    

 

	(c)		For purposes of this Agreement, the Exercise Date shall be the date on which the executed
Exercise Notice shall have been delivered to the Company. Except to the extent the sale and remittance procedure specified above
is utilized in connection with the warrant exercise, payment of the Warrant Price for the purchased shares must accompany such
Exercise Notice.

 

	(d)		Upon such exercise, the Company shall issue and cause to be delivered with all reasonable
dispatch (and in any event within three business days of such exercise) to or upon the written order of the Holder at its address,
and in the name of the Holder, a certificate or certificates for the number of full Warrant Shares issuable upon the exercise
together with such other property and securities as may then be deliverable upon such exercise. Such certificate or certificates
shall be deemed to have been issued and the Holder shall be deemed to have become a holder of record of such Warrant Shares as
of the Exercise Date.

 

	2.		The Warrant Shares have not and may not be registered as of the date of exercise of
this warrant under the Securities Act or the securities laws of any state. This warrant and the Warrant Shares issuable on exercise
of the warrant, when and if issued, are and may be "restricted securities" as defined in Rule 144 promulgated by the
Securities and Exchange Commission and must be held indefinitely unless subsequently registered under the Securities Act and any
other applicable state registration requirements, or an exemption from such registration requirements for resale is available.
The Company is under no obligation to register the securities under the Securities Act or under applicable state statutes. In
the absence of such a registration or an available exemption from registration, sale of the Warrant Shares will be prohibited.
The Holder shall confirm to the Company the representations set forth above in connection with the exercise of all or any portion
of this warrant.

 

	3.		The Company, during the term of this Agreement, will obtain from the appropriate regulatory
agencies any requisite authorization in order to issue and sell such number of shares of its Common Stock as shall be sufficient
to satisfy the requirements of the Agreement.

 

	4.		The number of Warrant Shares purchasable upon the exercise of this warrant and the
Warrant Price per share shall be subject to adjustment from time to time subject to the following terms. If the outstanding shares
of Common Stock of the Company are increased, decreased, changed into or exchanged for a different number or kind of shares of
the Company through reorganization, recapitalization, reclassification, stock dividend, stock split or reverse stock split, the
Company or its successors and assigns shall make an appropriate and proportionate adjustment in the number or kind of shares,
and the per-share Warrant Price thereof, which may be issued to the Holder under this Agreement upon exercise of the warrants
granted under this Agreement. The purchase rights represented by this warrant shall not be exercisable with respect to a fraction
of a share of Common Stock. Any fractional shares of Common Stock arising from the dilution or other adjustment in the number
of shares subject to this warrant shall be rounded up to the nearest whole share.

 

	5.		The Company covenants and agrees that all Warrant Shares which may be delivered upon
the exercise of this warrant will, upon delivery, be free from all taxes, liens, and charges with respect to the purchase thereof;
provided, that the Company shall have no obligation with respect to any income tax liability of the Holder.

 

	6.		The Company agrees at all times to reserve or hold available a sufficient number of
shares of Common Stock to cover the number of Warrant Shares issuable upon the exercise of this and all other warrants of like
tenor and other convertible securities then outstanding.

 

    	12

    	 

    

 

7.This warrant shall
not entitle the Holder hereof to any voting rights or other rights as a shareholder of the Company, or to any other rights whatsoever,
except the rights herein expressed, and no dividends shall be payable or accrue in respect of this warrant or the interest represented
hereby or the Warrant Shares purchasable hereunder until or unless, and except to the extent that, this warrant shall be exercised.

 

8.The Company may deem
and treat the registered owner of this warrant as the absolute owner hereof for all purposes and shall not be affected by any notice
to the contrary.

 

9.In the event that
any provision of this Agreement is found to be invalid or otherwise unenforceable under any applicable law, such invalidity or
unenforceability shall not be construed as rendering any other provisions contained herein invalid or unenforceable, and all such
other provisions shall be given full force and effect to the same extent as though the invalid or unenforceable provision were
not contained herein.

 

10.This Agreement shall
be governed by and construed in accordance with the internal laws of the state of Delaware, without regard to the principles of
conflicts of law thereof.

 

11.In case this warrant
shall be mutilated, lost, stolen, or destroyed, the Company may at its discretion issue and deliver in exchange and substitution
for and on cancellation of the mutilated warrant, or in lieu of and substitution for the warrant lost, stolen, or destroyed, a
new warrant of like tenor and representing an equivalent right or interest; but only on receipt of evidence satisfactory to the
Company of such loss, theft, or destruction of this warrant and indemnity satisfactory to the Company. The Holder shall also comply
with such other reasonable regulations and pay such other reasonable charges as the Company may prescribe.

 

12.This Agreement shall
be binding on and inure to the benefit of the Company and the person to whom a warrant is granted hereunder, and such person's
heirs, executors, administrators, legatees, personal representatives, assignees, and transferees.

 

IN WITNESS WHEREOF, the Company has caused
this warrant to be executed by the signature of its duly authorized officer, effective this ____day of _________2013.

 

	 	VIRAL GENETICS, INC.
	 	 
	 	By:__________________
	 	Its:______________

 

    	13

    	 

    

 

Exercise Notice

(to be signed only upon exercise of warrant)

 

TO: VIRAL GENETICS, INC.

 

The Holder of the attached warrant hereby irrevocable
elects to exercise the purchase rights represented by the warrant for, and to purchase thereunder, ________________ shares of common
stock of Viral Genetics, Inc., and herewith makes payment therefor, and requests that the certificate(s) for such shares be delivered
to the Holder at

 

_______________________________

_______________________________

_______________________________

 

If acquired without registration
under the Securities Act of 1933, as amended ("Securities Act"), the Holder represents that the Common Stock is being
acquired without a view to, or for, resale in connection with any distribution thereof without registration or other compliance
under the Securities Act and applicable state statutes, and that the Holder has no direct or indirect participation in any such
undertaking or in the underwriting of such an undertaking. The Holder understands that the Common Stock has not been registered,
but is being acquired by reason of a specific exemption under the Securities Act as well as under certain state statutes for transactions
by an issuer not involving any public offering and that any disposition of the Common Stock may, under certain circumstances, be
inconsistent with these exemptions. The Holder acknowledges that the Common Stock must be held and may not be sold, transferred,
or otherwise disposed of for value unless subsequently registered under the Securities Act or an exemption from such registration
is available. The Company is under no obligation to register the Common Stock under the Securities Act, except as provided in the
Agreement for the warrant. The certificates representing the Common Stock will bear a legend restricting transfer, except in compliance
with applicable federal and state securities statutes.

 

The Holder agrees and acknowledges
that this purported exercise of the warrant is conditioned on, and subject to, any compliance with requirements of applicable federal
and state securities laws deemed necessary by the Company.

 

DATED this _____day of ___________________

 

 

________________________

Signature                                      

    	14

    	 

    

 

Transfer Form

 

FOR VALUE RECEIVED, ______________________hereby sell, assign, and
transfer unto:

 

________________________

________________________

________________________

 

warrants to purchase shares of the Common Stock
of Viral Genetics, Inc., represented by the within instrument, and do hereby irrevocably constitute and appoint:

 

_______________________________________

 

to transfer said warrants stock on the books
of the within named Corporation with full power of substitution in the premises.

 

Dated __________________________, _____________________.

 

 

_____________________________

Signature

In presence of

 

_________________________________

 

    	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]